Cambridge Healthtech Institute’s 12th Annual

Advances in Vaccine Technologies

Delivering Innovative Solutions to Improve Global Health
August 29-30, 2017 | Sheraton Boston | Boston, MA

Vaccine technology has evolved significantly in the last decade, profoundly changing the future of vaccine development. The urgent need to accelerate response time to emerging threats, make vaccines more widely available and ready for quick deployment, develop vaccines against difficult targets, and improve delivery systems for maximum potency have been the impetus behind many advances in vaccine technology. Synthetic vaccine candidates, genomic analysis of disease progression and vaccine response, structure-based antigen design, and nanoparticle delivery systems are just a few of the realizations of this effort. CHI’s Twelfth Annual Advances in Vaccine Technologies will present the latest advancements and applications of vaccine technology, and a look forward to overcoming current challenges.

Preliminary Agenda


The Next Generation of Vaccines for Emerging Pathogens

Kayvon Modjarrad, M.D., Ph.D., Associate Director, Emerging Infectious Disease Threats, Walter Reed Army Institute of Research

Novel Vaccine Technologies against Emerging Viruses

Peter Pushko, Ph.D., President & CSO, Medigen


A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Safe and Effective in Neonates

Martha Alexander-Miller, Ph.D., Chair & Professor, Microbiology & Immunology, Wake Forest School of Medicine

Influenza Vaccines

Harry Kleanthous, Ph.D., Associate Vice President, Head, Research (North America), Sanofi Pasteur

Results of a Ph1a Study of M2SR Influenza Vaccine in Healthy Adults

Pamuk Bilsel, Ph.D., CSO, FluGen


DNA Immunization: From Vaccines to mAbs

Shan Lu, M.D., Ph.D., Professor, Medicine, University of Massachusetts Medical School

DNA Vaccines for Therapeutic Treatment of Cancer

Emma Masteller, Ph.D., Senior Director, Immuno-Oncology R&D, Inovio Pharmaceuticals


Harnessing the Immunogenicity of Foreign Viral CMV Antigens to Target Solid Tumors

David E. Anderson, Ph.D., CSO, VBI Vaccines

ATLAS™ Technology Identifies Unique Candidate Antigens for Potential Personalized Cancer Vaccines

Wendy Broom, Ph.D., Associate Director, Innovation and Automation, Genocea Biosciences

For more details on the conference, please contact:
Virginia Maxwell
Senior Associate Producer

For exhibit & sponsorship opportunities, please contact: 
Rod Eymael
Manager, Business Development

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today